Feature | Published:

Off-label or off-limits?

Nature Biotechnology volume 26, pages 867875 (2008) | Download Citation

Subjects

Off-label prescribing is a fundamental fact of life of healthcare systems, but the promotion of off-label uses by drug sponsors is a fundamental sin. Regulators, legislators and drug makers are wrestling to find the right balance.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Amgen and Enbrel marketing: crossing another line? Pharmalot (February 6, 2008)

  2. 2.

    et al. Arch. Intern. Med. 166, 1021–1026 (2006).

  3. 3.

    Ann. Oncol. 18, 1923–1925 (2007).

  4. 4.

    BBC News. Tighter drug trial laws promised, March 6, 2008.

  5. 5.

    , & Ann. Oncol. 14, 42–47 (2003).

  6. 6.

    Ann. Oncol. 14, 1–5 (2003).

  7. 7.

    The FDA contradicts Genentech on eye drug. The Wall Street Journal Health Blog (June 17, 2008)

  8. 8.

    & N. Engl. J. Med. 308, 1457–1463 (1983).

  9. 9.

    et al. N. Engl. J. Med. 327, 168–173 (1992).

Download references

Author information

Author notes

    • Mark Ratner

    Mark Ratner is a contributing writer to FDC-Windhover and a contributing editor to Nature Biotechnology.

Affiliations

  1. Trisha Gura is a Boston-based writer and former Knight fellow.

    • Trisha Gura

Authors

  1. Search for Mark Ratner in:

  2. Search for Trisha Gura in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt0808-867

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing